In 2005, a twice-daily injectable drug derived from Gila monster saliva entered the market with modest fanfare. Nobody predicted what it would become. Twenty years later, GLP-1 receptor agonists are the most talked-about class of medications on earth — prescribed for diabetes, obesity, cardiovascular disease, sleep apnea, and increasingly studied for addiction, Alzheimer’s, and kidney disease. The mechanism is elegant, the weight loss is real, and the side effects are significant enough to know before you start.
GLP-1 (glucagon-like peptide-1) is a hormone your gut naturally releases after eating. It does several things at once: it signals the pancreas to release insulin in a glucose-dependent manner (meaning it only triggers insulin when blood sugar is actually elevated, which is why GLP-1s have a low hypoglycemia risk on their own), it suppresses glucagon (the hormone that raises blood sugar between meals), it slows gastric emptying so food moves through your stomach more slowly, and it acts on appetite centers in the brain — particularly the hypothalamus — to reduce hunger and increase satiety.
The natural GLP-1 hormone breaks down in your bloodstream within minutes. GLP-1 receptor agonists are engineered versions that resist that breakdown, lasting hours to days to a full week depending on the drug.
Tirzepatide (Mounjaro, Zepbound) adds a second mechanism: it also activates GIP receptors (glucose-dependent insulinotropic polypeptide), making it a dual agonist. This dual action appears to be why tirzepatide produces greater weight loss than semaglutide in head-to-head trials — roughly 20% body weight vs. 15%.
The current gold standard for weight loss. Tirzepatide is a dual GIP/GLP-1 receptor agonist developed by Eli Lilly. Mounjaro was FDA-approved in May 2022 for Type 2 diabetes. Zepbound received approval in November 2023 specifically for obesity, and in December 2024 for moderate-to-severe obstructive sleep apnea. Both are the same drug — tirzepatide — at the same doses (2.5mg to 15mg weekly), just with different labels and different insurance coverage pathways.
The SURPASS-2 trial comparing tirzepatide to semaglutide showed tirzepatide at 15mg reduced HbA1c by 2.46% vs. 2.08% for semaglutide 1mg, and produced 11.2 lbs more weight loss. The SURMOUNT-1 obesity trial showed a mean 20.9% body weight reduction at the highest dose over 72 weeks. No prior drug has produced results like this in a broad population.
Semaglutide is the drug that changed the cultural conversation. Ozempic (0.5mg–2mg weekly injectable) was approved in December 2017 for T2D and became the drug everyone was talking about by 2022 when its weight-loss effects went viral. Rybelsus (3mg–14mg oral, taken fasting each morning) was approved in 2019 — the first oral GLP-1. Wegovy (2.4mg weekly) was approved in 2021 for obesity.
The SUSTAIN-6 cardiovascular outcomes trial (2016) showed semaglutide reduced major adverse cardiovascular events (MACE) by 26% vs. placebo. The SELECT trial (2023) extended this: semaglutide reduced CV events by 20% even in people without diabetes — just obesity. In August 2025, Wegovy became the first GLP-1 approved for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver condition closely tied to T2D.
Standard dosing for Ozempic: start 0.25mg weekly for 4 weeks, increase to 0.5mg, then 1mg or 2mg as tolerated. For weight loss (Wegovy): titrate up to 2.4mg over 16–20 weeks.
Approved in September 2014, Trulicity was a commercial success because of its delivery device — a pre-filled, auto-inject pen that many patients found easier to use than competitors. Weekly dosing (0.75mg or 1.5mg). The REWIND cardiovascular outcomes trial (2019) showed Trulicity reduced MACE by 12% in patients with T2D who had or were at high risk for CV disease. HbA1c reduction: approximately 0.7–1.4%. Weight loss: modest, 3–5 lbs on average, making it less favored now that higher-performing options exist.
Liraglutide was the drug that proved GLP-1s could protect the heart. Approved for T2D in January 2010 (daily injection), the LEADER trial (2016) showed liraglutide reduced CV death by 13% and overall mortality by 15% — landmark data that changed prescribing guidelines. Saxenda (3mg daily) received obesity approval in 2014. Weight loss: average 8–10 lbs in trials. HbA1c reduction: approximately 1.0–1.5%. Now largely replaced by weekly options, but the CV outcomes data remain foundational.
Byetta (exenatide, twice daily) was the first GLP-1 receptor agonist ever approved — April 2005 — and it was derived from a protein in Gila monster saliva called exendin-4. It was remarkable science. Twice-daily injections before meals limited its appeal. Bydureon, the extended-release weekly version, followed in 2012. By 2020, both were largely obsolete as semaglutide and tirzepatide arrived. HbA1c reduction: 0.5–1.0%. Weight loss: 4–6 lbs. Still occasionally used in patients with specific insurance or tolerance issues.
Microdosing refers to using semaglutide or tirzepatide at doses significantly below the FDA-approved starting amounts — typically 0.05mg to 0.125mg weekly for semaglutide (vs. the standard 0.25mg starting dose). It emerged from online communities and compounding pharmacy ecosystems as a way to reduce GI side effects, extend supply during shortages, and lower cost.
The evidence is limited but not nothing. One study found participants taking 1mg semaglutide weekly lost an average of 16% body weight over 64 weeks — nearly matching results at the full 2.4mg dose. The theory: GLP-1 appetite suppression may plateau at lower doses for many individuals, meaning higher doses don’t always produce proportionally better outcomes.
Platforms offering structured microdosing programs include Noom Med, Ro, and various telehealth compounding services. Compounded semaglutide was widely available during the 2022–2024 shortage period. The FDA flagged safety concerns about compounded versions in 2024 — specifically around dosing errors with acetate salt formulations vs. the sodium salt used in FDA-approved products. Standard brand-name Ozempic and Wegovy use semaglutide sodium. Some compounders used semaglutide acetate, which requires different dosing math that patients sometimes got wrong.
Bottom line on microdosing: It may work, it may be cheaper, and the side effect profile may be milder. It should only be done under physician supervision with a clearly defined compounded product. Do not attempt to stretch or split your Ozempic pen without medical guidance.
Ranked by mean HbA1c reduction and weight loss at highest approved doses:
| Drug | HbA1c Reduction | Weight Loss | CV Outcomes Trial |
|---|---|---|---|
| Tirzepatide 15mg | −2.46% | −20.9% | SURPASS-CVOT (pending full pub) |
| Semaglutide 2.4mg | −2.0% | −14.9% | SUSTAIN-6, SELECT |
| Semaglutide 1mg | −1.5% | −6.5 kg | SUSTAIN-6 |
| Liraglutide 1.8mg | −1.1% | −3.7 kg | LEADER (−13% CV death) |
| Dulaglutide 1.5mg | −1.4% | −3 kg | REWIND (−12% MACE) |
| Exenatide 2mg | −1.0% | −2–3 kg | EXSCEL (neutral) |
Gastrointestinal — by far the most common. Nausea affects 15–44% of users at initiation. Vomiting, diarrhea, and constipation are also reported. These typically improve after 4–8 weeks as your body adjusts, and are substantially reduced by slow dose titration. Taking the injection at night rather than morning, eating smaller meals, and avoiding high-fat foods in the first weeks all help significantly.
Gastroparesis — GLP-1s slow gastric emptying as part of their mechanism. For most people this is a feature. For a subset, especially long-term users, it can become pathological — causing persistent nausea, early satiety, and vomiting even when not eating. A 2023 study in JAMA found GLP-1 users had 3.7× higher risk of gastroparesis diagnosis compared to non-GLP-1 diabetes patients. Risk appears higher with longer use and higher doses.
Thyroid C-cell tumors — GLP-1 receptors are expressed on thyroid C-cells in rodents, and GLP-1 agonists caused dose-dependent C-cell tumors in rat and mouse studies. This is the basis of the black box warning. The human clinical relevance remains uncertain — humans have far fewer thyroid C-cell GLP-1 receptors than rodents — but GLP-1s are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2).
Pancreatitis — Rare but serious. Early post-market surveillance raised concerns and the FDA added a warning in 2009. Subsequent meta-analyses have not confirmed a statistically significant increase in absolute risk, but the signal remains. Discontinue immediately if you develop severe, persistent abdominal pain that radiates to the back.
Gallbladder disease — Significant weight loss accelerates cholesterol gallstone formation. GLP-1 users have approximately 2× the risk of gallstones and cholecystitis vs. non-users. This is partly a mechanism effect and partly a consequence of rapid weight loss.
Muscle loss — A real concern with rapid weight loss at high GLP-1 doses. Studies suggest that 25–40% of weight lost on GLP-1s can be lean mass (muscle), not fat, particularly without resistance exercise. This matters a great deal for metabolic health, insulin sensitivity, and longevity. If you are on a GLP-1, resistance training is not optional — it’s essential.
Vision changes — Rapid improvement in blood glucose can temporarily worsen diabetic retinopathy. This is a known paradox: getting your sugar under control fast causes short-term retinal stress. If you have pre-existing diabetic eye disease, get a baseline retinal exam before starting and monitor closely in the first 6 months.
Ileus (intestinal blockage), 2023 — The FDA added a warning for ileus — a serious condition where the intestines stop moving — following case reports in GLP-1 users. GI motility is reduced with these drugs, and in rare cases this can escalate to a surgical emergency.
Anesthesia aspiration risk, 2023–2024 — The American Society of Anesthesiologists issued guidance in 2023 recommending GLP-1 patients hold their medication for at least one week before elective surgery. Slowed gastric emptying means stomach contents may not clear even after a standard fasting period, raising aspiration risk during general anesthesia. If you need surgery, tell your anesthesiologist you are on a GLP-1.
Mental health signal, 2023 — The FDA and European Medicines Agency both investigated reports of suicidal ideation and self-harm in GLP-1 users. After review, neither agency found a causal link. The signals may reflect underlying conditions in the patient populations. The investigation is considered closed as of 2024, but clinicians are advised to monitor patients with prior psychiatric history.
Compounded semaglutide safety alert, 2024 — During the Ozempic/Wegovy shortage period (2022–2024), compounding pharmacies produced semaglutide at large scale. The FDA flagged that some compounders used semaglutide acetate salt instead of the sodium salt in brand-name products, requiring different dose calculations. Multiple reports of dosing errors — some resulting in hospitalizations — prompted the alert. When the shortage was resolved in late 2024, the FDA moved to restrict compounding of semaglutide.
GLP-1s have not been around long enough to have truly long-term data (20+ years). What we know from 5–8 year follow-ups:
Weight regain after stopping is significant. The STEP-4 trial showed that patients who discontinued semaglutide regained roughly two-thirds of their lost weight within one year. This has sparked debate about whether GLP-1s should be considered chronic medications — like antihypertensives — rather than courses of treatment.
The cardiovascular data is increasingly robust. LEADER, SUSTAIN-6, REWIND, and SELECT together represent tens of thousands of patients showing consistent MACE reduction. This is not surrogate data — it’s hard endpoint reduction in real patients.
Emerging 2025–2026 research is examining GLP-1s in Alzheimer’s disease (the GLP-1 receptor is expressed in the brain and may reduce neuroinflammation), addiction and substance use disorders (early signals showing reduced alcohol and opioid cravings), non-alcoholic fatty liver disease (NASH/MASH), and polycystic ovary syndrome (PCOS). The drug class appears to have systemic anti-inflammatory effects that extend well beyond glucose and weight.
The muscle loss issue remains the most significant unresolved concern for long-term users. Studies examining optimal protein intake and resistance training protocols alongside GLP-1 therapy are ongoing but not yet definitive.
Please understand that I’m not a doctor, and everything on this site reflects my own research and personal experience managing Type 2 diabetes. It is provided for informational and educational purposes only — not as medical advice, diagnosis, or treatment.
Before starting any supplement, changing your diet, or adjusting your medications, consult your physician or a qualified healthcare provider. Individual results vary. Never delay or disregard professional medical advice because of something you read here.
Product photos and brand names appear for illustrative purposes only. Denyabetic does not endorse, sponsor, or have any commercial relationship with any brand shown unless explicitly stated.
These statements have not been evaluated by the Food and Drug Administration. No product or protocol discussed on this site is intended to diagnose, treat, cure, or prevent any disease.